Bryan Garnier - Pharmaceuticals: Reporting season in the US: read across for European players under coverage

Report

Bryan Garnier

Eric Le Berrigaud

Pharmaceuticals: Reporting season in the US: read across for European players under coverage

Pharmaceuticals
Reporting season in the US: read across for European players under coverage

Minor changes to 2020 guidance overall
Q1 largely helped by Otezla and biosimilars
Strong growth reported by AbbVie for Venclexta

04/05/2020 3 EN

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Eric Le Berrigaud

Other Reports from Bryan Garnier

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Waga Energy: CAD25m debt refinancing

Yesterday, Waga Energy announced it has secured a CAD25m (~EUR16m) non-recourse loan from Equitable Bank and Empire Life. The 19-year non-recourse financing is dedicated to the refinancing of three operating RNG production units, namely Saint-Étienne-des-Grés, Chicoutimi, and Cowansville in Quebec.

July 4, 2025 July 4, 2025 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Avantium: FDCA included in Japan's "Positive List"

This morning, Avantium announced that Japan has officially included FDCA (2,5-furandicarboxylic acid) on its Positive List for food contact plastics. The Positive List system is part of Japan’s Food Sanitation Law and was introduced in 2020 to enhance consumer safety, only permitting pre-approved c

July 3, 2025 July 3, 2025 1 EN

Maria Vara

Maria Vara

Median Technologies: CE mark filing keep eyonis on track, US launch before YE

Yesterday post-market, Median announced that it has submitted the Class IIb CE marking filing for eyonis LCS, just a month after the FDA 510(k) submission, precisely sticking to the company's timeline guidance. Our confidence in a positive outcome remains high, as both submissions are underpinned b

July 2, 2025 July 2, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Pharmaceuticals: Reporting season in the US: read across for European players under coverage

Waga Energy: CAD25m debt refinancing

Avantium: FDCA included in Japan's "Positive List"

Median Technologies: CE mark filing keep eyonis on track, US launch before YE

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe